Table 2.

Primary and secondary efficacy endpoints in phase III trials of avatrombopag for the management of periprocedural thrombocytopenia in CLD

Primary or Secondary Endpoint	ADAPT-1 (Avatrombopag vs Placebo)		ADAPT-2 (Avatrombopag vs Placebo)
Low baseline platelet count	High baseline platelet count	Low baseline platelet count	High baseline platelet count
Percentage of patients not requiring transfusion or rescue for bleeding (low baseline platelet count)	66% vs 23%	88% vs 38%	69% vs 35%	88% vs 33%
Percentage of patients achieving the target platelet count of ≥50×109/L on procedure day	69% vs 4.2%	88% vs 21%	67% vs 7%	93% vs 39%
Change in platelet count from baseline to procedure day	32.0×109/L vs 0.8×109/L	37.1×109/L vs 1.0×109/L	31.3×109/L vs 3.0×109/L	44.9×109/vs 5.9×109/L